Apellis’s Pegcetacoplan Hits 'Grand Slam' Scenario In Rare Kidney Disease
A Phase III trial testing pegcetacoplan in patients with two rare kidney diseases demonstrated impressive efficacy, outperforming what Novartis showed with Fabhalta in a similar trial.
